LC-MS based bioanalysis of peptides has become highly sensitive, and LGC has developed LC-MS/MS methods capable of detecting and quantifying peptides in plasma down to 10-15 pg/mL.
A major issue with peptide drugs is their inherent instability, due to the numerous classes of peptidases present. We have experience in assessing peptide stability both in-vitro (in plasma and serum) and in-vivo, as many peptides are susceptible to degradation by endogenous peptidases.
Using the variety of mass spectrometers at our disposal, our scientists can also identify breakdown products (metabolites) and develop methods to quantify them. Our expertise extends beyond determination of peptide drugs in biological matrices. We also have experience in the quantitation of proteins (therapeutic drugs and biomarkers) as well as mAbs using our BioMS™ platform.